Imatinib, a potent and selective protein tyrosine kinase inhibitor, has been approved for the treatment of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. In vitro metabolism of imatinib was investigated in rat and human liver microsomes. Besides several oxidative metabolites and an N-desmethyl metabolite, as previous reported, a novel metabolite with a mass addition of 621 atomic mass units to the parent was detected as the major metabolite in the incubations with rat liver microsomes, using NADPH as a cofactor. Imatinib (Gleevec) is an anticancer drug that selectively inhibits the BCR-ABL tyrosine kinase, ␣-and ␤-platelet-derived growth factor receptors, as well as c-Kit receptor tyrosine kinase (Capdeville et al., 2002; Savage and Antman, 2002) . The metabolism and disposition of imatinib was investigated in healthy volunteers after a single oral dose of 239 mg of 14 C-labeled imatinib mesylate (Gschwind et al., 2005) . Approximately 65 and 9% of the total systemic exposure corresponded to imatinib and its active N-desmethyl metabolite, respectively. In the excreta, imatinib and its N-desmethyl metabolites accounted for 28 and 13% of administrated dose, respectively. The remaining proportion represented mainly oxidative metabolites and N-or O-glucuronides. Thus, imatinib was predominantly cleared through oxidative metabolism in humans. Imatinib was metabolized in vitro mainly by CYP3A4 and to a lesser extent by CYP1A2, CYP2C9, CYP2C19, and CYP2D6 (Peng et al., 2005) . In the present study, we report the detection and structural characterization of novel adenine dinucleotide phosphate (ADP ϩ ) adducts of imatinib after incubations with rat and human liver microsomes (HLM).
Imatinib (Gleevec) is an anticancer drug that selectively inhibits the BCR-ABL tyrosine kinase, ␣-and ␤-platelet-derived growth factor receptors, as well as c-Kit receptor tyrosine kinase (Capdeville et al., 2002; Savage and Antman, 2002) . The metabolism and disposition of imatinib was investigated in healthy volunteers after a single oral dose of 239 mg of 14 C-labeled imatinib mesylate (Gschwind et al., 2005) . Approximately 65 and 9% of the total systemic exposure corresponded to imatinib and its active N-desmethyl metabolite, respectively. In the excreta, imatinib and its N-desmethyl metabolites accounted for 28 and 13% of administrated dose, respectively. The remaining proportion represented mainly oxidative metabolites and N-or O-glucuronides. Thus, imatinib was predominantly cleared through oxidative metabolism in humans. Imatinib was metabolized in vitro mainly by CYP3A4 and to a lesser extent by CYP1A2, CYP2C9, CYP2C19, and CYP2D6 (Peng et al., 2005) . In the present study, we report the detection and structural characterization of novel adenine dinucleotide phosphate (ADP ϩ ) adducts of imatinib after incubations with rat and human liver microsomes (HLM).
Materials and Methods
Materials. Imatinib mesylate was purchased from AK Scientific Inc. (Mountain View, CA). Rat liver microsomes (RLM; lot no. 33152) and HLM (lot no. 36170) were obtained from BD Gentest (Woburn, MA). Formic acid was purchased from Pierce (Rockford, IL). Methanol, acetonitrile, and water were obtained from Thermo Fisher Scientific (Waltham, MA). NADPH, NADP ϩ , and NAD glycohydrolase from porcine brain were purchased from Sigma-Aldrich (St. Louis, MO). In Vitro Incubations. Imatinib (10 M) was incubated with 1 mg/ml rat or HLM in 100 mM phosphate buffer, pH 7.4, containing 1 mM NADPH or NADP ϩ at 37°C for 1 h. Incubations of imatinib with boiled RLM in the presence of NADPH or NADP ϩ were also performed as negative controls.
Imatinib (10 M) was also incubated with NAD glycohydrolase (NADase; 5 mg/ml suspension in 100 mM phosphate buffer) containing 1 mM NADP ϩ at 37°C for 1 h. The total incubation mixture was 500 l. The incubations were quenched with 250 l of acetonitrile. The samples were then mixed on a vortex mixer and centrifuged at 14,000 rpm for 10 min. An aliquot of 20 l was injected into the liquid chromatography-mass spectrometry (LC-MS) system for analysis. Analytical Methods. The LC-MS system consisted of an Agilent 1100 HPLC system (Agilent Technologies, Santa Clara, CA) and a LTQ mass spectrometer (Thermo Fisher Scientific). Separation was achieved on an YMC basic column (2.0 ϫ 150 mm, 5 m; Waters, Milford, MA) at a flow rate of 0.2 ml/min. Mobile phases consisting of 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B) were used under the following gradient conditions: 0 to 3 min, 10% B; 3 to 45 min, 10 to 50% B; 45 to 46 min, 50 to 95% B; 46 to 50 min, 95% B; 50 to 51 min, 95 to 10% B; and 51 to 56 min, 10% B. The UV detector was set at a wavelength of 270 nm. The LTQ mass spectrometer was operated in the positive ion mode with an electrospray ionization source. The ion source conditions were as follows: spray voltage, 5 kV; sheath and auxiliary gas (N 2 ) flow, 60 and 10 (arbitrary units), respectively; capillary voltage, 48 V; tube lens, 136 V; capillary temperature, 250°C. Tandem mass spectrometry (MS/MS), MS 3 , and MS 4 experiments were performed under collision energy of 20 to 30% with an isolation mass window of 2 Da. Metabolite Isolation for NMR. A scale-up (20 ml) incubation was carried out using RLM under the same incubation conditions as described above. The sample was extracted using Sep-Pak C-18 cartridge (Waters) and further purified using an Alliance 2690 separations module (Waters) on a YMC-Pack ODS-AQ column (10 ϫ 250 mm, 5 m; Waters). Same mobile phases were 
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622used under the following gradient conditions: 0 to 3 min, 10% B; 3 to 8 min, 10 to 30% B; 8 to 35 min, 30 to 36% B; 35 to 36 min, 36 to 95% B; 36 to 40 min
Results and Discussion
In addition to several oxidation metabolites and an N-desmethyl metabolite, as reported previously (Gschwind et al., 2005; Marull and Rochat, 2006) , three novel conjugates (M1, m/z 1101; M2, m/z 1115; and M3, m/z 1131) resulted from 621 atomic mass units addition to N-desmethyl imatinib, imatinib, and imatinib N-oxide, respectively, were detected in the rat liver microsome incubations in the presence of NADPH. M2 was the major metabolite and accounted for 36% of the total UV profile (at 270 nm), whereas M1 and M3 were detected as minor peaks (Ͻ5% of the UV profile). Only trace levels of M1 and M2 (Ͻ2% of the UV profile) were detected in the incubations with HLM in the presence of NADPH.
The MS/MS spectrum of M2 showed major fragment ions at m/z 494, 604, and 622, 490, 410 (Fig. 1A) . The presence of fragment ion at m/z 494 suggested that imatinib moiety remained intact. The MS 3 spectrum of m/z 558 (ϩ2) 3 622 3 showed a major fragment ion from loss of a water and two other minor fragments at m/z 490 and 410 (Fig. 1B) . The MS 4 product ion spectrum of m/z 558 (ϩ2) 3 622 3 604 3 showed fragmentation patterns that were essentially identical to that of 744 3 622 3 604 3 from NADP ϩ (Fig. 1 , C and D), which suggested that M2 was an ADP ϩ adduct of imatinib. NMR data confirmed the proposed structure and conclusively showed that the conjugation had occurred on the pyridine nitrogen. dmd.aspetjournals.org
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The proton NMR spectrum of M2, displayed in Fig. 2A , showed the presence of protons from both imatinib and the ADP ϩ moiety (Table  1) . Protons H26 and H27 (from pyridine moiety) and H1Ј (from ADP ϩ ribose ring) appeared at 9.68, 9.37, and 6.22 ppm, respectively. A cross-peak was observed from H1Ј (at 6.22 ppm) and H26 in the ROESY spectrum (Fig. 2B) . Furthermore, a heteronuclear multiplebond correlation was observed from H1Ј to C26 (139.5 ppm; data not shown). A complete listing of proton and carbon chemical shifts is provided in Table 1 .
The MS/MS spectrum of M1 at m/z 551 (ϩ2) showed major fragment ions at m/z 480, 604, 622, 490, and 410 (data not shown). The MS 3 spectrum of m/z 551 (ϩ2) 3 480 3 gave fragment ions at m/z 394 and 203, which indicated that M1 was an ADP ϩ adduct of N-desmethyl imatinib. The MS/MS spectrum of M3 at m/z 566 (ϩ2) showed major fragment ions at m/z 510, 604, 622, 490, and 410 (data not shown). The MS 3 spectrum of m/z 566 (ϩ2) 3 510 3 was identical with the MS/MS of imatinib N-oxide (N-oxidation on the methylpiperazine). Therefore, M3 was proposed as the ADP ϩ adduct of imatinib N-oxide.
To investigate whether NADP ϩ is the reactant for the formation of imatinib-ADP ϩ adducts, the incubation of imatinib with rat liver microsomes in the presence of NADP ϩ was performed. As shown in Fig. 3A , a peak at retention time 25.6 min with m/z 558 (ϩ2) was detected. The MS/MS product ion spectrum showed fragment ions at m/z 494, 604, and 622, 490, 410. The MS 4 spectrum of m/z 558 (ϩ2) 3 622 3 604 3 gave same fragment ions and showed the same fragmentation pattern with that from M2. This peak was absent in the incubations without NADP ϩ or rat liver microsomes. Imatinib-ADP ϩ adducts were not detected in the incubations with boiled RLM in the presence of NADPH or NADP ϩ . Therefore, the formation of ADP ϩ adduct was inferred to be an enzymatic reaction that required the presence of NADP ϩ as a reactant. The ADP ϩ adducts of imatinib have been observed only in in vitro studies to date. Their in vivo relevance remains to be determined.
The enzyme NADase was shown to catalyze transglycosylation reaction to form ADP ϩ conjugates of a number of pyridine containing compounds, including cotinine (Shen et al., 1977) , 3-acetyl pyridine (Kaplan and Ciotti, 1956) , nicotinic acid (Bernofsky, 1980) , nicotinic acid hydrazine (Zatman et al., 1954) , and 6-aminocotinamide (Dietrich et al., 1958) , nitrosamines (Peterson et al., 1994) , and thiophenopyridine-containing IB kinase ␤ inhibitors (Miao et al., 2005) . To investigate whether imatinib is a substrate of this enzyme, imatinib was incubated with NADP ϩ and NADase. As shown in Fig.  3B , a peak at a retention time of 25.5 min was detected with m/z 558 (ϩ2). MS 2 and MS 3 fragmentation patterns matched with those of ADP ϩ conjugates of imatinib (M2). Its formation was dependent on the presence of both NADP ϩ and NADase. Therefore, imatinib is a substrate for this transglycosylation catalyzed by NADase.
NAD glycohydrolase catalyzes the cleavage of the nicotinamideribose bond of NADP ϩ to generate an enzyme-stabilized oxocarbenium ion-type intermediate and transfer of the ADP-ribosyl group to an acceptor, such as water (hydrolysis), methanol (methanolysis), or pyridine-containing compounds (transglycosidation) (Tarnus et al., 1988; Muller-Steffner et al., 1996) . NAD glycohydrolase is found to be ubiquitous in many organisms from bacteria to mammals (Han et al., 1995) . The physiological and toxicological roles of this enzyme involved in the formation of drug-ADP ϩ adducts are not well understood (Peterson et al., 1994; Hecht, 1998) .
In summary, novel adenine dinucleotide phosphate (ADP ϩ ) adducts of imatinib and its major metabolites were identified and characterized by LC-MS/MS and NMR. The enzyme involved in the formation of ADP ϩ adducts was also identified.
